Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 16Dermatologic 7Gynecologic 6Thoracic 4Gastrointestinal 4Breast 3Plasma cell 2Head & Neck 2Genitourinary 2CNS 2

Conditions

Breast Neoplasms 555Triple Negative Breast Neoplasms 94Inflammatory Breast Neoplasms 38Breast Neoplasms, Male 31Neoplasm Metastasis 27Ovarian Neoplasms 25Carcinoma, Non-Small-Cell Lung 23Melanoma 21Pancreatic Neoplasms 14Neoplasms 14Colorectal Neoplasms 13Carcinoma, Renal Cell 12Stomach Neoplasms 11Multiple Myeloma 10Lung Neoplasms 10Carcinoma, Ovarian Epithelial 9Carcinoma, Hepatocellular 9Lymphoma, Non-Hodgkin 8Sarcoma 7Lymphoma, Follicular 7Lymphoma 7Carcinoma, Ductal, Breast 7Recurrence 6Neutropenia 6Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid, Acute 6Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

Cyclophosphamide 3pembrolizumab 1fludarabine 1aldesleukin 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Mass Spectrometry 1Interleukin-2 1Immunotherapy 1Imatinib Mesylate 1Drug Therapy 1Chromatography, High Pressure Liquid 1Biological Therapy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sarcoma, Synovial × Cyclophosphamide × Breast × Clear all
NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Valo Therapeutics Oy

Phase 1 Recruiting
15 enrolled
BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

Phase 1/2 Recruiting
3 enrolled
BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Shenzhen Second People's Hospital

Phase 1 Unknown
36 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡